How to Pick the Right CDMO: The Definitive Playbook for Pharma IP Teams, Portfolio Managers, and R&D Leads
Executive Summary The global CDMO market hit USD 238.92 billion in 2024 and is on track to reach USD 465.24
August 2023
Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry
The Inevitable Horizon: Understanding Loss of Exclusivity (LOE) The pharmaceutical landscape is characterized by cycles of innovation, market exclusivity, and
Why Biosimilar Filings Fail: The Complete Technical Guide to 351(k) Rejections, CRL Patterns, and CMC Pitfalls
1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience.
AI in Drug Discovery: The Complete Technical and IP Strategy Guide for Pharma Executives
1. Why Traditional Drug R&D Is Structurally Broken Between 2000 and 2015, more than 86% of drug candidates that entered
AI in Drug Discovery: The Complete Technical and IP Strategy Guide for Pharma Executives Read Post »
Authorized Generics: The Complete Data Playbook on Prevalence, Timing, and Market Impact
An authorized generic is a brand-name drug sold under a generic label. No new FDA approval required. No new manufacturing
Authorized Generics: The Complete Data Playbook on Prevalence, Timing, and Market Impact Read Post »
FDA Orange Book vs. Biologic PTAB: The Data-Driven Patent Strategy Guide Pharma Can’t Ignore
The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider,
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide
Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide Read Post »
Authorized Generics: The Brand’s Last Weapon Against Generic Entry (And What It Costs Everyone Else)
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
